Allergy immunotherapy (AIT)

Phase 3Small molecule

AALK-Abelló A/S

Allergy immunotherapy (AIT) is one of 90 small molecule programs targeting Allergy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

Allergic RhinitisActive, not recruiting

Eosinophilic EsophagitisActive, not recruiting

AllergyPhase 3

Active, not recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Eosinophilic EsophagitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Kenalog

BBassett Healthcare

Phase 3

1 3

Experimental

Biogen

Phase 3

1 4

GW685698X

GSK

Phase 3

5 5

Allergy immunotherapy (AIT)

AALK-Abelló A/S

Phase 3

1 6

Allegra-D

Pfizer

Phase 3

3 7

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

3 8

Asmanex

Novartis

Preclinical

12 9

Ismigen

LLallemand Pharma AG

Phase 3

1 10

GSP 301 NS

GGlenmark Specialty S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

Allergy Immunotherapy in the Management of Eosinophilic Esophagitis

Withdrawn·UUnited States Naval Medical Center, San Diego·N/A·NCT01685034

Allergy1 trial

House Dust Mite Allergy Trial In Children

Completed·AALK-Abelló A/S·Phase 3·NCT04145219·1,460 enrolled

Allergic Rhinitis1 trial

Impact of AIT on Allergic Rhinitis and Asthma

Completed·AALK-Abelló A/S··NCT04125888·92,048 enrolled

Unspecified1 trial

Intraseasonal Short-time Up-dosing With Alutard SQ Grasses

Completed·AALK-Abelló A/S·Phase 3·NCT00807547·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Allergy immunotherapy (AIT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergy immunotherapy (AIT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergy immunotherapy (AIT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ALK-Abelló A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AALK-Abelló A/S

Allergy immunotherapy (AIT)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eosinophilic Esophagitis1 trial

Allergy1 trial

Allergic Rhinitis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News